Policy

Trump Moves Ahead With Drug Import Plan

July 25th 2020

By Skylar Jeremias

President Trump signed 4 executive orders that would lower prices of prescriptions medications including insulin products and cancer medicines.

Webinar: Choice Is Vital to Biosimilar Savings Picture

July 21st 2020

By Tony Hagen

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16th 2020

By Tony Hagen

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.

House Committee Calls for CMS Action on Biosimilars

July 15th 2020

By Tony Hagen

The House Appropriations Committee has called upon CMS to increase access to biosimilars.

Remove the Disincentives and Biosimilars Will Flourish, Policy Expert Says

July 7th 2020

By Tony Hagen

Wayne Winegarden, PhD, director of the Center for Medical Economics and Innovation, explains that misaligned incentives are preventing the United States from realizing full benefit from biosimilars.

IQVIA Rates European Countries on Biosimilar Market Health

June 30th 2020

By Tony Hagen

A new scorecard system developed by IQVIA rates the health and sustainability of biosimilars markets across Europe.

Part 2: Christine Simmon Discusses Payer Influence on Provider Behavior

June 18th 2020

Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discussed the new pathway for insulin biosimilars and the struggles between payers and providers over biosimilar choice.

Panel Discusses Need for Drug Supply Chain Reforms

June 18th 2020

By Skylar Jeremias

In response to pharmaceutical supply chain disruptions caused by the coronavirus disease 2019 (COVID-19) pandemic, a panel of experts called for big changes; attention to detail is key to making sure the outcomes are successful.

Rising Costs Explain Why Canada Is Switching to Biosimilars

June 15th 2020

By Skylar Jeremias

Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars initiatives that would switch patients from some of the most costly reference biologics to biosimilar counterparts.

Part 3: Axinn Attorneys Discuss Patent Exclusivity and the BPCIA

May 8th 2020

Ted Mathias and Stacie Ropka, PhD, both patent attorneys and partners at Axinn, Veltrop and Harkrider LLP, discuss patent exclusivity for biological drugs and other important issues that need to be addressed whether or not the ACA and the Biologics Price Competition and Innovation Act (BPCIA) are ruled invalid.